← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Organon & Co. (OGN) 10-Year Financial Performance & Capital Metrics

OGN • • Industrial / General
HealthcareLarge PharmaPlasma & Biologics ManufacturersPlasma & Blood Products Specialists
AboutOrganon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.Show more
  • Revenue $6.4B +2.2%
  • EBITDA $1.76B +12.8%
  • Net Income $864M -15.5%
  • EPS (Diluted) 3.33 -16.5%
  • Gross Margin 58.02% -3.0%
  • EBITDA Margin 27.53% +10.3%
  • Operating Margin 23.21% +9.5%
  • Net Margin 13.49% -17.4%
  • ROE 429.85%
  • ROIC 13.11% +3.3%
  • Debt/Equity 19.14
  • Interest Coverage 2.86 +13.5%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Excellent 3Y average ROE of 429.9%
  • ✓Healthy 5Y average net margin of 19.8%

✗Weaknesses

  • ✗High debt to equity ratio of 19.1x
  • ✗Profits declining 23.1% over 5 years
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-3.81%
3Y0.52%
TTM-1.69%

Profit (Net Income) CAGR

10Y-
5Y-23.12%
3Y-13.84%
TTM-61.49%

EPS CAGR

10Y-
5Y-23.5%
3Y-14.51%
TTM-61.9%

ROCE

10Y Avg26.07%
5Y Avg21.97%
3Y Avg16.98%
Latest15.22%

Peer Comparison

Plasma & Blood Products Specialists
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
GRFSGrifols, S.A.2.31B8.9338.839.41%4.96%4.94%23.02%1.17
OGNOrganon & Co.2.26B8.702.612.24%7.95%55.3%26%19.14

Profit & Loss

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+9.78B7.78B6.53B6.3B6.17B6.26B6.4B
Revenue Growth %--0.2%-0.16%-0.03%-0.02%0.01%0.02%
Cost of Goods Sold+4.69B2.27B2.12B2.38B2.29B2.52B2.69B
COGS % of Revenue0.48%0.29%0.32%0.38%0.37%0.4%0.42%
Gross Profit+5.08B5.5B4.41B3.92B3.88B3.75B3.71B
Gross Margin %0.52%0.71%0.68%0.62%0.63%0.6%0.58%
Gross Profit Growth %-0.08%-0.2%-0.11%-0.01%-0.03%-0.01%
Operating Expenses+2.38B1.66B1.57B2.01B2.17B2.42B2.23B
OpEx % of Revenue0.24%0.21%0.24%0.32%0.35%0.39%0.35%
Selling, General & Admin2.01B1.44B1.36B1.67B1.7B1.89B1.76B
SG&A % of Revenue0.21%0.19%0.21%0.26%0.28%0.3%0.27%
Research & Development365M220M210M443M471M528M469M
R&D % of Revenue0.04%0.03%0.03%0.07%0.08%0.08%0.07%
Other Operating Expenses000-104M000
Operating Income+2.71B3.85B2.85B1.92B1.71B1.33B1.49B
Operating Margin %0.28%0.49%0.44%0.3%0.28%0.21%0.23%
Operating Income Growth %-0.42%-0.26%-0.33%-0.11%-0.22%0.12%
EBITDA+4.38B4.2B2.99B2.11B1.92B1.56B1.76B
EBITDA Margin %0.45%0.54%0.46%0.33%0.31%0.25%0.28%
EBITDA Growth %--0.04%-0.29%-0.29%-0.09%-0.18%0.13%
D&A (Non-Cash Add-back)1.67B354M142M195M212M236M277M
EBIT2.71B3.56B2.85B1.79B1.54B1.2B1.33B
Net Interest Income+013M-6M-258M-422M-527M-520M
Interest Income019M00000
Interest Expense06M6M258M422M527M520M
Other Income/Expense23M-144M-95M-386M-583M-654M-679M
Pretax Income+2.73B3.7B2.75B1.53B1.12B673M807M
Pretax Margin %0.28%0.48%0.42%0.24%0.18%0.11%0.13%
Income Tax+576M390M496M178M205M-350M-57M
Effective Tax Rate %0.79%0.87%0.78%0.88%0.82%1.52%1.07%
Net Income+2.15B3.22B2.16B1.35B917M1.02B864M
Net Margin %0.22%0.41%0.33%0.21%0.15%0.16%0.13%
Net Income Growth %-0.49%-0.33%-0.37%-0.32%0.12%-0.16%
Net Income (Continuing)2.15B3.31B2.26B1.35B917M1.02B864M
Discontinued Operations00-96M0000
Minority Interest0000000
EPS (Diluted)+8.5112.718.525.333.593.993.33
EPS Growth %-0.49%-0.33%-0.37%-0.33%0.11%-0.17%
EPS (Basic)8.5112.718.525.333.614.013.36
Diluted Shares Outstanding253.13M253.13M253.52M253.55M255.17M256.27M259.15M
Basic Shares Outstanding253.13M253.13M253.52M253.55M254.08M255.24M257.05M
Dividend Payout Ratio---0.11%0.32%0.29%0.34%

Balance Sheet

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+3.71B3.96B3.57B3.76B3.93B4.51B4.35B
Cash & Short-Term Investments244M319M12M737M706M693M675M
Cash Only244M319M12M737M706M693M675M
Short-Term Investments0000000
Accounts Receivable1.59B1.57B1.41B1.51B1.61B1.86B1.49B
Days Sales Outstanding59.4773.8378.5187.5494.94108.2284.99
Inventory994M1.07B913M915M1B1.31B1.32B
Days Inventory Outstanding77.31171.91157.27140.21159.59190.84179.38
Other Current Assets883M992M1.24B596M616M643M861M
Total Non-Current Assets+6.78B6.59B6.54B6.92B7.02B7.55B8.75B
Property, Plant & Equipment651M762M1.01B1.2B1.23B1.36B1.32B
Fixed Asset Turnover15.02x10.21x6.44x5.24x5.01x4.62x4.83x
Goodwill4.6B4.6B4.6B4.6B4.6B4.6B4.68B
Intangible Assets812M569M503M651M649M533M1.41B
Long-Term Investments00000027M
Other Non-Current Assets714M659M421M464M272M250M361M
Total Assets+10.49B10.55B10.11B10.68B10.96B12.06B13.1B
Asset Turnover0.93x0.74x0.65x0.59x0.56x0.52x0.49x
Asset Growth %-0.01%-0.04%0.06%0.03%0.1%0.09%
Total Current Liabilities+1.54B1.34B2.67B2.6B2.51B2.92B2.72B
Accounts Payable289M258M259M1.38B1.13B1.31B1.15B
Days Payables Outstanding22.4841.4144.61211.77180.11190.7156.56
Short-Term Debt115M48M8M55M57M55M64M
Deferred Revenue (Current)1000K000000
Other Current Liabilities6M793M2.12B975M1.14B1.34B1.37B
Current Ratio2.40x2.95x1.33x1.45x1.56x1.54x1.60x
Quick Ratio1.76x2.15x0.99x1.10x1.17x1.09x1.11x
Cash Conversion Cycle114.3204.32191.1615.9874.42108.37107.81
Total Non-Current Liabilities+2.6B2.17B1.95B9.59B9.34B9.21B9.91B
Long-Term Debt34M70M09.13B8.9B8.75B8.86B
Capital Lease Obligations068M23M184M150M125M112M
Deferred Tax Liabilities149M139M128M4M19M47M74M
Other Non-Current Liabilities2.57B1.9B1.8B279M261M287M865M
Total Liabilities4.15B3.51B4.62B12.19B11.85B12.13B12.63B
Total Debt+149M186M31M9.36B9.11B8.93B9.04B
Net Debt-95M-133M19M8.63B8.41B8.24B8.36B
Debt / Equity0.02x0.03x0.01x---19.14x
Debt / EBITDA0.03x0.04x0.01x4.44x4.75x5.71x5.13x
Net Debt / EBITDA-0.02x-0.03x0.01x4.09x4.38x5.27x4.74x
Interest Coverage-641.17x474.50x7.42x4.04x2.52x2.86x
Total Equity+6.35B7.04B5.49B-1.51B-892M-70M472M
Equity Growth %-0.11%-0.22%-1.27%0.41%0.92%7.74%
Book Value per Share25.0827.7921.64-5.95-3.50-0.271.82
Total Shareholders' Equity6.35B7.04B5.49B-1.51B-892M-70M472M
Common Stock7.26B7.95B6.11B3M3M3M3M
Retained Earnings000-998M-331M443M1.01B
Treasury Stock0000000
Accumulated OCI-908M-914M-622M-513M-564M-541M-649M
Minority Interest0000000

Cash Flow

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+3.69B2.77B2.19B2.46B858M799M939M
Operating CF Margin %0.38%0.36%0.33%0.39%0.14%0.13%0.15%
Operating CF Growth %--0.25%-0.21%0.12%-0.65%-0.07%0.18%
Net Income2.15B3.31B2.26B1.35B917M1.02B864M
Depreciation & Amortization1.67B333M142M195M212M236M277M
Stock-Based Compensation56M41M40M59M75M101M105M
Deferred Taxes37M12M-32M-288M-18M-485M-160M
Other Non-Cash Items-58M-253M-22M439M124M79M131M
Working Capital Changes-174M-672M-197M702M-452M-155M-278M
Change in Receivables250M200M159M-277M-123M-212M383M
Change in Inventory44M-91M-29M-138M-220M-230M-131M
Change in Payables20M-35M27M663M-237M163M-157M
Cash from Investing+-69M-102M-258M-481M-420M-260M-513M
Capital Expenditures-101M-92M-278M-488M-427M-259M-351M
CapEx % of Revenue0.01%0.01%0.04%0.08%0.07%0.04%0.05%
Acquisitions-------
Investments-------
Other Investing32M-17M15M192M131M1M4M
Cash from Financing+-4.16B-2.62B-2.17B-1.33B-433M-569M-368M
Debt Issued (Net)-------
Equity Issued (Net)-------
Dividends Paid000-145M-290M-294M-297M
Share Repurchases-------
Other Financing-4.22B-2.62B-3.69B-9.03B-24M0-38M
Net Change in Cash-------
Free Cash Flow+3.59B2.67B1.91B1.97B431M538M588M
FCF Margin %0.37%0.34%0.29%0.31%0.07%0.09%0.09%
FCF Growth %--0.25%-0.29%0.03%-0.78%0.25%0.09%
FCF per Share14.1710.577.537.771.692.102.27
FCF Conversion (FCF/Net Income)1.71x0.86x1.01x1.82x0.94x0.78x1.09x
Interest Paid00000495M0
Taxes Paid0000000

Key Ratios

Metric2018201920202021202220232024
Return on Equity (ROE)33.92%48.09%34.5%67.92%--429.85%
Return on Invested Capital (ROIC)32.46%43.87%34.42%22.75%17.48%12.69%13.11%
Gross Margin52%70.76%67.56%62.21%62.84%59.84%58.02%
Net Margin22.02%41.38%33.07%21.43%14.85%16.33%13.49%
Debt / Equity0.02x0.03x0.01x---19.14x
Interest Coverage-641.17x474.50x7.42x4.04x2.52x2.86x
FCF Conversion1.71x0.86x1.01x1.82x0.94x0.78x1.09x
Revenue Growth--20.46%-16.01%-3.49%-2.06%1.44%2.24%

Revenue by Geography

2021202220232024
Europe And Canada---1.76B
Europe And Canada Growth----
UNITED STATES--1.48B1.57B
UNITED STATES Growth---6.36%
Asia Pacific and Japan1.17B1.14B1.13B1.05B
Asia Pacific and Japan Growth--2.56%-1.22%-7.00%
Latin America, Middle East, Russia And Africa---1.03B
Latin America, Middle East, Russia And Africa Growth----
CHINA933M917M864M847M
CHINA Growth--1.71%-5.78%-1.97%
Other Countries233M151M154M137M
Other Countries Growth--35.19%1.99%-11.04%
Europe and Canada1.74B1.63B1.67B-
Europe and Canada Growth--6.32%2.58%-
Latin America, Middle East, Russia and Africa841M895M965M-
Latin America, Middle East, Russia and Africa Growth-6.42%7.82%-

Frequently Asked Questions

Valuation & Price

Organon & Co. (OGN) has a price-to-earnings (P/E) ratio of 2.6x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Organon & Co. (OGN) reported $6.30B in revenue for fiscal year 2024. This represents a 36% decrease from $9.78B in 2018.

Organon & Co. (OGN) grew revenue by 2.2% over the past year. Growth has been modest.

Yes, Organon & Co. (OGN) is profitable, generating $501.0M in net income for fiscal year 2024 (13.5% net margin).

Dividend & Returns

Yes, Organon & Co. (OGN) pays a dividend with a yield of 13.17%. This makes it attractive for income-focused investors.

Organon & Co. (OGN) has a return on equity (ROE) of 429.9%. This is excellent, indicating efficient use of shareholder capital.

Organon & Co. (OGN) generated $566.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.